Abivax SA (ABVX) vs Cytokinetics (CYTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Cytokinetics (CYTK) has outperformed Abivax SA (ABVX) over the past year, gaining 1.6% versus a gain of 0.0%. Cytokinetics is the larger company by market cap ($8.50 billion vs $7.59 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | CYTK |
|---|---|---|
| Share price | $87.01 | $61.12 |
| Market cap | $7.59B | $8.50B |
| 1-day change | -1.37% | -0.37% |
| YTD return | -35.48% | -3.81% |
| 1-year return | 0.00% | +1.58% |
| 5-year return | — | +65.68% |
| EPS (TTM) | $-6.08 | $-7.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $88.04M |
| Revenue growth (YoY) | — | +376.56% |
| Net income (latest FY) | — | $-784.96M |
| Operating margin | — | -695.44% |
| Net margin | — | -891.60% |
| 52-week high | $148.83 | $88.31 |
| 52-week low | $69.81 | $54.30 |
| Distance from 52-week high | -41.54% | -30.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.48% | +79.81% |
| Average volume | 1.09M | 1.96M |
| Shares outstanding | 87.27M | 139.02M |
| Employees | 98 | 673 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
ABVX vs CYTK FAQ
Which is bigger, Abivax SA or Cytokinetics?
Cytokinetics (CYTK) is larger, with a market capitalization of $8.50B compared with $7.59B for Abivax SA (ABVX).
Which stock has performed better over the past year, ABVX or CYTK?
CYTK returned +1.58% over the past 12 months, compared with 0.00% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Cytokinetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.